Hua is a leading, clinical stage innovative drug development company in China focused on novel therapies for the treatment of diabetes. Founded by an experienced group of entrepreneurs and international investment firms, Hua advanced a first-in-class oral drug for the treatment of Type 2 Diabetes into NDA enabling stage and started 2 Phase 3 trials in China for drug naive and metformin treated T2D patients. The company also has initiated product life-cycle management studies of this novel diabetes drug, and advanced knowledge in personalized diabetes care. Hua's strategy is to leverage the cost-efficient and high-quality drug development capabilities available in China, while working very closely with disease experts in China and rest of world to advance diabetes care solutions for global patients.
Hua Medicine (the “Company”, Stock Code on The Stock Exchange of Hong Kong Limited: 2552.HK), a global innovative drug research and development company focused on novel therapies for the treatment of diabetes, today announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2019.
Franz Matschinsky, Professor of Biochemistry and Biophysics, Institute for Diabetes, Obesity and Metabolism Perelman School of Medicine, Philadelphia, was awarded the Rolf Luft Award 2020.
Copyright © 2020 Hua Medicine, All Rights Reserved